|Bid||14.54 x 100|
|Ask||14.56 x 300|
|Day's Range||14.24 - 14.73|
|52 Week Range||11.30 - 67.90|
|PE Ratio (TTM)||4.53|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Otonomy shares rose in premarket trading on Aug. 31 after plunging Wednesday on the heels of disappointing data in a Phase 3 study of Otividex in patients with Meniere's disease.
Q2 2017 Merrimack Pharmaceuticals Inc Earnings Call
Merrimack Pharmaceuticals (MACK) reported wider-than-expected loss in the second quarter. With no marketed product after Onivyde sale, the company is now focused on developing its pipeline candidates.